Navigation Links
Children's Hospital leads projects to develop nation's first heart assist devices for young children
Date:4/3/2008

n the laboratory and hopes to begin the clinical trial in the coming year. The device, known as the PediVAS (ventricular assist system), would be an external pump designed to support pediatric patients in heart failure for days to four weeks.

Dr. Wearden also is spearheading efforts to develop the first totally implantable pediatric VAD in the United States that could be used for longer periods of time than the external pump.

In the development of an implantable pediatric VAD known as PediaFlow, Childrens team is partnering with two pioneers in cardiac support, Harvey S. Borovetz, PhD, deputy director, Artificial Organs and Medical Devices, McGowan Institute for Regenerative Medicine, and chair, Department of Bioengineering, University of Pittsburgh; and James Antaki, professor, Department of Biomedical Engineering, Carnegie Mellon University.

Industry partners in the consortium include Launch Point Technologies (Santa Barbara, Calif.) and WorldHeart Corporation (Salt Lake City).

This project, also funded by the NIH (one of only five centers in the nation to receive NIH funding for such a project), has progressed through an intensive engineering design phase to successful testing in the laboratory. The consortium is entering the final year of the five-year NIH contract to develop the PediaFlow.

Our dream for the PediaFlow which is about the size of a walnut is that it could be totally implanted into a child to support his or her heart until a donor could be located or until the heart function recovers, Dr. Wearden said. The PediaFlow would be magnetically powered and potentially could support a child for as long as six months.

Under the leadership of Victor Morell, MD, chief of Childrens Division of Cardiothoracic Surgery, Childrens Heart Center has established itself as one of the most active and innovative centers in the care of children in heart failure in the country over the last two decades. Childrens ha
'/>"/>

Contact: Marc Lukasiak
marc.lukasiak@chp.edu
412-692-7919
Children's Hospital of Pittsburgh
Source:Eurekalert

0

GOOD

Page: 1 2 3

Related biology news :

1. Clinical trial that may help patients breathe easier begins at Central DuPage Hospital
2. MRSA in hospital intensive care -- whats growing where?
3. Texas Hospital nations first to use large-scale cocoon strategy against whooping cough
4. Pennsylvania Hospital recognized for excellence in bariatric surgery
5. Childrens Hospital neurosurgeon receives grant
6. Pennsylvania Hospital surgeon receives grant to develop molecular cardiac surgery
7. Childrens Hospital studying drug with the potential to prevent/delay onset of type 1 diabetes
8. Nationwide Childrens Hospital involved in expanded access program for treatment of PKU
9. 3 out of 4 hospital patients suffer from malnutrition regardless of their pathology
10. Seattle Childrens Hospital leads $23.7 million NIH grant to study gene repair
11. Study finds environmental tests help predict hospital-acquired Legionnaires disease risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)Our ability to learn new information and adapt to changes in our daily environment, as well as to retain lifelong memories, appears to lie in the minute junctions where nerve cells communicate, accord
(Date:12/3/2009)Contents of this message: , , Preliminary Press Conference Topics, Last Call! Press Field Trip to California Academy of Sciences museum, Attention PIOs: Sending Press Releases to Fall meeting, N
(Date:12/3/2009)Grand Rapids, Mich. (Dec. 3, 2009) Van Andel Research Institute (VARI) researchers have determined precisely how the plant hormone abscisic acid (ABA) works at the molecular level to help plants re
Breaking Biology News(10 mins):Lifelong memories linked to stable nerve connections 2AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 2AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 3AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 4AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 5AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 6VAI researchers find long awaited key to creating drought resistant crops 2VAI researchers find long awaited key to creating drought resistant crops 3Sakayu Shimizu of Kyoto University recipient of 2009 Enzyme Engineering Award 9960 1Sakayu Shimizu of Kyoto University recipient of 2009 Enzyme Engineering Award 9960 2Regulatory role of key molecule discovered at Hebrew U 9958 1MedTrust Online Surpasses 5 000 Registered Users and Adds Dr Henry Friedman to Oncology Advisory Board 14120 1MedTrust Online Surpasses 5 000 Registered Users and Adds Dr Henry Friedman to Oncology Advisory Board 14120 2
... scientists, including a team from The University ... (IMB), is a step closer to the next generation of...comprehensive analysis of the human and mouse tran...nd IMB researcher Professor David Hume said transc... the genome by a cell at any given time. , "Esse...
...rnational Rice Research Institute (IRRI) is workin...South East Asian Nations (ASEAN) to develop a seri... in the region. , When implemented, the indicators...e environmental impact of its rice production with...blems or improve on existing practices. It,s the f...
... isn,t really that sluggish after all. So says the...e creature,s behavior in the wild, which was just ...l Bulletin. , The new research is significant bec...dibranch mollusc species found in the shallow nort...of the how the brain controls behavior, a field kn...
Other Biology News:Learning the language of DNA 2A cleaner, greener rice industry 2The secret lives of sea slugs 2
(Date:12/3/2009)SAN FRANCISCO, Dec. 3 VIA Pharmaceuticals, Inc. (Nasdaq: VIAP ), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today anno
(Date:12/3/2009)WALTHAM, Mass., Dec. 3 Inverness Medical Innovations, Inc. (NYSE: IMA ), a global leader in enabling individuals to take charge of their health at home through the merger of rapid diagnostics and h
(Date:12/2/2009)COLUMBIA, Md., Dec. 2 Martek Biosciences Corporation (Nasdaq: MATK ) announced today that it intends to release the results of its fourth quarter and fiscal year 2009 on December 16, 2009, at approx
(Date:12/2/2009)NEW YORK, Dec. 2 Reportlinker.com announces that a new market research report is available in its catalogue: ,, Carbondioxide Incubators - A Global Market Perspective ,, http://www.reportlinker.co
Breaking Biology Technology:VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 4Martek to Announce Fourth Quarter and Fiscal Year 2009 Results 2Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 2Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 3Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 4
...n collaboration with the Chinese Academy of Scienc...tation of molecules on a fixed surface to understa...rotor-based machinery at nanoscale level. , The...ch play an important part in machines like electri...logy at the atomic scale is to replicate this prop...
...RCROSS, Ga., May 27 Immucor, Inc. (Nasdaq: BLUD...ent-reagent systems to the blood transfusion indus...r agreement with Alverno Clinical Laboratories, LL... integrated delivery systems in the nation, servin...r the agreement, Alverno is standardizing pre-tran...
...rst clinical study evaluating DUROS(R) continuous ...diabetes , , HAYWARD, Calif., May 27 Intarcia Th...linical data from a phase 1b study of ITCA 650 (DU...reatment of type 2 diabetes as a late-breaker at t...ciation in New Orleans, LA (June 5-9, 2009). The s...
Other Biology Technology:Immucor and Alverno Clinical Laboratories Sign Five-Year Automation Agreement 2Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions 2Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions 3
cAMP Competitive immunoassay Assay Kit, HTRF from Cisbio
...in filters allow for the rapid isolation of DNA fr...ice in the spin filter, centrifuge for 3 minutes, ...s no need to melt agarose or use any special buff...ange, primer removal from PCR reactions, and remov...
Human Atherosclerosis Antibody Array I Kit, ChemiArray, 20 cytokines per membrane from CHEMICON
High-Binding EIA 96 Well Strip Plates from Cayman Chemical
Biology Products: